ZB-004 is under clinical development by Zenas BioPharma (USA) and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZB-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZB-004 overview

ZB-004 (XmAb-10717) is under development for the treatment of autoimmune diseases. The therapeutic candidate is a extended Fc fusion protein being developed based on Xmab technology platform. It is administered through subcutaneous route.

Zenas BioPharma (USA) overview

Zenas BioPharma (USA) (Zenas) is a biopharmaceutical company. The company focuses on a rapidly advancing portfolio of innovative therapeutics. Its product pipeline includes Obexelimab (XmAb5871), ZB002, ZB004, ZB001 (IV)3, ZB011 (SC)3, and ZB0054. The company’s Obexelimab demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases and IgG4-related disease (IgG4-RD); ZB001 is same as insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb) which is used in treatment of thyroid eye disease (TED); ZB002 used in anti-TNFa therapies; and ZB004 used in CTLA4-Ig fusion protein therapies. It operated across the US. Zenas is headquartered in Waltham, Massachusetts, the US.

For a complete picture of ZB-004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.